Protective Effects of Edaravone Dexborneol

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of imaging and the improvement of NIHSS and mRS in different groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lili Cao; Qianfoshan Hospital
• Treatments: Edaravone

Criteria

Inclusion Criteria:

1. Aged from 50 to 80 years old;

2. Patients diagnosed as acute ischemic stroke according to Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018 and who met the requirements of middle cerebral artery blood supply area infarction (except deep perforator disease) without treatment;

3. Brain MR showed that the low perfusion area of ASL was at least 20% larger than that of DWI core infarct area, and the contralateral mirror brain tissue was basically normal;

4. NIHSS score was between 4 to 24;

5. Patient or their legal representatives were willing to sign the informed consent form.

Exclusion Criteria:

1. Serious mental abnormality, complicated with heart, lung, liver, renal insufficiency or malignant tumor and other serious diseases;

2. Combined with cerebral vascular malformation or cerebral hemorrhage;

3. Pregnant or lactating women;

4. Allergic to edaravone or dexborneol;

5. There are interactions between the drugs being taken by patients and the study drug or affect the clinical trial parameters.